

Comparison of two bundles for reducing surgical site infection in colorectal surgery: multicentre cohort study

Miriam Flores-Yelamos^{1,2} (D), Aina Gomila-Grange³ (D), Josep M. Badia^{1,2,*} (D), Alexander Almendral⁴ (D), Ana Vázquez⁵ (D), David Parés⁶ (D), Marta Pascual⁷ (D), Enric Limón^{4,8,9} (D), Miquel Pujol^{4,9,10} (D), Montserrat Juvany⁷ (D) and members of the VINCat Colorectal Surveillance Team

¹Department of Surgery, Hospital General de Granollers, Granollers, Spain

- ²School of Medicine, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain
- ³Department of Infectious Diseases, Hospital Universitari Parc Taulí, Sabadell, Spain

⁴Surveillance of Healthcare Related Infections in Catalonia Programme, VINCat, Departament de Salut, Generalitat de Catalunya, Catalonia, Spain

⁵Servei d'Estadística Aplicada, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain

⁶Colorectal Surgery Unit, Department of Surgery, Hospital Universitari Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Barcelona, Spain ⁷Department of Surgery, Hospital del Mar, Barcelona, Spain

⁸Department of Public Health, Mental Health & Mother–Infant Nursing, Faculty of Nursing, University of Barcelona, Barcelona, Spain

⁹Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain

¹⁰Department of Infectious Diseases, Hospital Universitari de Bellvitge—IDIBELL, L'Hospitalet de Llobregat, Spain

*Correspondence to: Josep M. Badia, Department of Surgery, Hospital General de Granollers, Av Francesc Ribas 1, 08402 Granollers, Barcelona, Spain (email: jmbadiaperez@gmail.com)

Members of the VINCat Colorectal Surveillance Team are co-authors of this study and are listed under the heading Collaborators.

Abstract

Background: There is controversy regarding the maximum number of elements that can be included in a surgical site infection prevention bundle. In addition, it is unclear whether a bundle of this type can be implemented at a multicentre level.

Methods: A pragmatic, multicentre cohort study was designed to analyse surgical site infection rates in elective colorectal surgery after the sequential implementation of two preventive bundle protocols. Secondary outcomes were to determine compliance with individual measures and to establish their effectiveness, duration of stay, microbiology and 30-day mortality rate.

Results: A total of 32 205 patients were included. A 50% reduction in surgical site infection was achieved after the implementation of two sequential sets of bundles: from 18.16% in the Baseline group to 10.03% with Bundle-1 and 8.19% with Bundle-2. Bundle-2 reduced superficial-surgical site infection (OR 0.74 (95% c.i. 0.58 to 0.95); P = 0.018) and deep-surgical site infection (OR 0.66 (95% c.i. 0.46 to 0.93); P = 0.018) but not organ/space-surgical site infection (OR 0.88 (95% c.i. 0.74 to 1.06); P = 0.172). Compliance increased after the addition of four measures to Bundle-2. In the multivariable analysis, for organ/space-surgical site infection, laparoscopy, oral antibiotic prophylaxis and mechanical bowel preparation were protective factors in colonic procedures, while no protective factors were found in rectal surgery. Duration of stay fell significantly over time, from 7 in the Baseline group to 6 and 5 days for Bundle-1 and Bundle-2 respectively (P < 0.001). The mortality rate fell from 1.4% in the Baseline group to 0.59% and 0.6% for Bundle-1 and Bundle-2 respectively (P < 0.001). There was an increase in Gram-positive bacteria and yeast isolation, and reduction in Gram-negative bacteria and anaerobes in organ/space-surgical site infection.

Conclusions: The addition of measures to create a final 10-measure protocol had a cumulative protective effect on reducing surgical site infection. However, organ/space-surgical site infection did not benefit from the addition. No protective measures were found for organ/space-surgical site infection in rectal surgery. Compliance with preventive measures increased from Bundle-1 to Bundle-2.

Introduction

Surgical site infection (SSI) is one of the most common healthcarerelated infections in Europe and also the most prevalent postsurgical complication^{1,2}. Although its incidence has fallen, it remains a significant healthcare concern due to its impact on hospital stay, antibiotic consumption, readmission and reoperation rates. It also impacts patients' outcomes by increasing the morbidity rate and reducing survival^{1,3–5}.

Colorectal surgery has the highest SSI rates of all surgical interventions, with a reported incidence of up to 26% compared with overall surgical rates below $6\%^2$. It has been estimated that

about 60% of SSIs are preventable^{6,7}. However, implementation of different preventative strategies has shown varying rates of success. In this context, the implementation of epidemiological surveillance programmes and preventive bundles has emerged as a promising strategy.

Bundles comprise limited sets of easy-to-implement and evidence-based preventive measures which, applied together, improve patients' outcomes. Designing and implementing bundles can be challenging; some have proven effectiveness in colorectal surgery^{8,9}, but others do not¹⁰. Most interventions impact on superficial SSI (S-SSI) rates and have less impact on deep (D-SSIs) and organ/space-SSI (O/S-SSIs)¹¹⁻¹³. Bundles may

 $\ensuremath{\mathbb O}$ The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

be relatively easy to introduce at single centres, but there is less evidence of the effectiveness of their implementation in large groups of hospitals^{14,15}. In this context, the successful implementation of bundles with small numbers of measures may take more than 4 years¹⁶.

It has been argued that increasing the number of interventions in a bundle reduces compliance. However, two meta-analyses on colorectal surgery found that bundles containing 11 elements or more demonstrated the greatest reduction in SSIs^{9,17}.

This study aimed to better understand the impact of adding new measures to an established bundle within a nationwide surveillance programme. Two bundles were compared to measure the effectiveness of each specific measure. One bundle comprised six measures and the other comprised 10 and were implemented sequentially in a large series of elective colorectal procedures from 2011 to 2022.

The hypothesis was that thorough introduction of a well designed, large bundle of best practice preventive measures would achieve good adherence and would reduce SSI rates after colorectal surgery.

Methods

Setting and patients

This pragmatic, multicentre cohort study comprised a network of 65 public and private hospitals that prospectively record data in order to reduce SSI rates and to improve other healthcare outcomes in elective colorectal surgery. The infection control team (ICT) at each hospital performed prospective surveillance to ensure adequate data collection with a minimum mandatory follow-up of 30 days after surgery, an electronic review of clinical records to record readmissions, visits to the emergency department or other healthcare facilities, and microbiological and radiological data. The data analysis and results were carried out retrospectively.

Patients who underwent elective colorectal surgery between January 2011 and December 2022 were included. Patients with wound class 2 (clean-contaminated) and 3 (contaminated), according to the National Healthcare Safety Network Classification¹⁸, were monitored. Patients with wound class 4 (peritonitis) and with previous ostomies were excluded. *Table S1* shows the inclusion and exclusion criteria for colorectal surgery surveillance in detail.

Three sequential phases were compared: a baseline interval before bundle implementation (Baseline group), from January 2011 to June 2016; a Bundle-1 interval after the implementation of a six-measure bundle (Bundle-1 group), from July 2016 to June 2018; and a Bundle-2 interval after the implementation of a 10-measure bundle (Bundle-2 group), from July 2018 to December 2022 (Fig. S1).

During the baseline interval, before the introduction of each bundle, detailed operational definition documents were generated annually and shared with all hospitals in the network, together with the annual performance benchmark. The implementation phases of each bundle began 3 months before the start, with dissemination of the recommended measures by e-mail to all participating hospitals, posting of the procedure manual on the surveillance system website, and a workshop for infection control groups from all hospitals, including surgeons, anaesthetists, surgical nursing teams and the ICT itself.

The definitions, criteria and surveillance methodology used by the ICT staff were identical in all three study intervals. ICTs were pretrained to ensure consistent and accurate data collection, and audits of the data provided were conducted at different points in the programme's development. A programme of continuing education for ICTs was also maintained throughout the surveillance programme, and personalized counselling was provided to ICTs when the SSI diagnosis was doubtful or other operational problems occurred. Mandatory active surveillance after discharge was conducted until postoperative day 30.

Data source, definitions, study outcomes and variables

The data were taken from the surveillance programme of healthcare-associated infection in Catalonia, Spain (VINCat), which performs prospective and interventional surveillance of SSIs at public and private hospitals.

The primary outcome was the development of an SSI according to the Centres for Disease Control (CDC) definitions within 30 days after surgery¹⁹. Incisional (I-SSI) includes S-SSI (skin and subcutaneous tissue involvement) and D-SSI (affects deep soft tissues), while O/S-SSI affects any anatomical structure other than the incision¹⁹. O/S-SSI is associated with a higher mortality rate and higher healthcare costs²⁰.

Secondary outcomes were to determine compliance with individual measures and their effectiveness, assessment of duration of stay (LOS), 30-day mortality rate and SSI-causing microorganisms.

Routine demographic data collected by the surveillance system were analysed, including age, sex, American Society of Anesthesiologists (ASA) surgical risk score, information on the surgical procedure (including open, laparoscopic or robotic approach), wound contamination class and duration of surgery. The term minimally invasive surgery (MIS) includes procedures performed by laparoscopic and robotic surgery. The National Nosocomial Infection Surveillance (NNIS) score was also calculated for each patient.

As a source of data on compliance with the measures included in the bundles, a checklist of prevention measures was generated for each bundle. The data from these checklists were prospectively transmitted online to the centralized database of the surveillance programme. The criteria used to consider antibiotic prophylaxis 'adequate' included: the type of drug, the dose administered, the timing of infusion, its completion before the surgical incision and the duration of therapy. A single deviation from the recommended guidelines was enough to consider the process inadequate.

Intervention

In the Baseline group, certain measures such as intravenous antibiotic prophylaxis and the use of laparoscopy were already included as standard clinical practices. In Bundle-1, six specific colorectal measures were recommended: intravenous antibiotic prophylaxis, laparoscopy, oral antibiotic prophylaxis (OAP), mechanical bowel preparation (MBP), maintenance of normothermia and double-ring plastic wound retractor. In Bundle-2, four additional general measures were incorporated: adequate hair removal, skin antisepsis with 2% chlorhexidine gluconate alcohol solution (CHG-alcohol), perioperative glucose monitoring and changing of instruments before wound closure. The measures implemented are described in *Table S2*.

Statistical analysis

Data were summarized using frequencies and proportions for categorical variables and means with standard deviation or

medians with interguartile range for continuous variables, depending on the distribution. The infection rate was expressed as the crude percentage of operations resulting in SSI per number of surgical procedures. To address confounding variables and to minimize selection bias among the three groups, inverse probability of treatment weighting (IPTW) was used^{21,22}. Preweighted groups were compared using Pearson's chi-square test or Fisher's exact test for categorical variables and Student's t-test or ANOVA for continuous variables. The effectiveness of IPTW in achieving a balance between confounding variables was assessed by comparing standardized differences between groups before and after weighting²³. The comparative assessment of outcomes between groups used univariate logistic regression for categorical outcomes and the Wilcoxon rank-sum test for continuous outcomes. Additionally, a univariable and multivariable logistic regression model based on unweighted cluster data was used to characterize the effect of specific measures on SSIs. The results of the logistic regression model were presented in terms of odds ratios (OR) along with their corresponding 95% confidence intervals (95% c.i.). The significance level was set at 0.05 for all tests. All results were analysed using R v4.2.2 software by The R Foundation, Vienna, Austria²⁴.

Ethical issues

The data are stored in a large, non-publicly available national database. The study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies²⁵, and was approved by the Clinical Research Ethics Committee of the Hospital General de Granollers, which considered that informed consent was not necessary given that the data were anonymized, and

Table 1 Characteristics of patients who underwent colorectal surgery during the study interval

Characteristics	Baseline group	Bundle-1	Bundle-2	Р
Colorectal surgery				
Number of procedures	18 664	3908	9633	
Sex				0.125
Male	11 345	2316	5772	
Female	7319	1592	3861	
Age (years), median (i.q.r.)	69.79 (60.90–78.32)	68.52 (60.97–77.26)	71.08 (61.84–79.05)	<0.001
Duration of intervention (min), median (i.q.r.)	165 (120–218)	164 (125–214)	176 (135–230)	<0.001
Clean-contaminated wound	18 038 (96.6)	3857 (98.7)	9544 (99.1)	<0.001
NISS > = 1	6263 (33.6)	929 (23.8)	2823 (29.3)	<0.001
ASA classification				<0.001
I	1045 (5.6)	221 (5.7)	413 (4.3)	
II	10 333 (55.4)	2260 (57.8)	5241 (54.4)	
III	6837 (36.6)	1378 (35.3)	3804 (39.5)	
IV	449 (2.4)	49 (1.3)	175 (1.8)	
MIS	10 986 (58.9)	2941 (75.3)	7760 (80.6)	<0.001
Adequate i.v. antibiotic prophylaxis	16 266 (87.2)	3187 (81.6)	8218 (85.3)	<0.001
Colon surgery				
Number of procedures	13 112	2834	7329	
Sex				0.095
Male	7753	1615	4278	
Female	5359	1219	3051	
Age (years), median (i.q.r.)	70.16 (61.20–78.66)	69.22 (61.62–77.94)	71.71 (62.39–79.27)	<0.001
Duration of intervention (min), median (i.q.r.)	150 (115–195)	151 (120–193)	165 (129–210)	<0.001
Clean-contaminated wound	12 737 (97.1)	2806 (99.0)	7289 (99.5)	<0.001
NISS > = 1	4452 (34.0)	6/1 (23./)	2203 (30.1)	<0.001
ASA classification				<0.001
	/34 (5.6)	161 (5.7)	314 (4.3)	
	/1/1 (54./)	1621 (57.2)	3960 (54.0)	
	4861 (37.1)	1019 (36.0)	2906 (39.7)	
IV	346 (2.6)	33 (1.2)	149 (2.0)	0.004
MIS	//23 (58.9)	2141 (75.5)	5827 (79.5)	<0.001
Adequate I.v. antibiotic prophylaxis	114/6 (87.5)	2322 (81.9)	6254 (85.3)	<0.001
Rectal surgery	FFFO	1074	2204	
Number of procedures	5552	1074	2304	0.026
JEX	3503	701	1404	0.930
Male	5592 1060	272	1494	
Age (vegee) medien (i.e.r.)			012	-0.001
Age (years), median (i.q.r.)	00.00 (00.31-77.33)	205(160,262)	09.45 (00.27-78.15)	<0.001
Clean contaminated wound	203 (130-203) 5201 (05 5)	1051 (07.0)	220 (1/0-2/3)	<0.001
	1911 (22 G)	258 (24 0)	620 (26 0)	<0.001
ASA classification	1011 (52.0)	238 (24.0)	020 (20.9)	0.001
I	211 (5 6)	60 (5 6)	99 (1 3)	0.002
I	3162 (57.0)	639 (59 5)	1281 (55.6)	
11 TIT	1976 (35.6)	359 (33.4)	898 (39 N)	
TV	103 (1 9)	16 (1 5)	26 (1 1)	
MIS	3263 (58.8)	800 (74 5)	1933 (83 9)	<0.001
Adequate i v antibiotic prophylaxis	4790 (86 3)	865 (80 5)	1964 (85.2)	<0.001
	1,00 (00.5)	005 (00.5)	1007 (00.2)	<0.001

Values are n (%) unless otherwise indicated. i.q.r., interquartile range; NNIS, National Nosocomial Infection Surveillance risk index; ASA, American Society of Anesthesiologists surgical risk score; i.v., intravenous; MIS, minimally invasive surgery.



Fig. 1 SSI rates throughout the study

SSI, surgical site infection; S-SSI, superficial surgical site infection; D-SSI, deep surgical site infection; O/S-SSI, organ-space surgical site infection.

Table 2 SSI rates in the three intervals

				Baseline group versus Bundle	(ref.) e-1	Baseline group versus Bundle	(ref.) e-2	Bundle-1 (ref.) versus Bundle-2	
SSI	Baseline group	Bundle-1	Bundle-2	OR (95% c.i.)	Р	OR (95% c.i.)	Р	OR (95% c.i.)	Р
Colorectal sur	gery								
Overall-SSI	3390 (18.16)	392 (10.03)	789 (8.19)	0.56 (0.50 to 0.63)	<0.001	0.44 (0.40 to 0.48)	<0.001	0.79 (0.69 to 0.91)	0.001
S-SSI	1119 (6)	125 (3.2)	213 (2.21)	0.59 (0.48 to 0.72)	<0.001	0.44 (0.37 to 0.52)	<0.001	0.74 (0.58 to 0.95)	0.018
D-SSI	569 (3.05)	58 (1.48)	97 (1.01)	0.55 (0.41 to 0.74)	<0.001	0.36 (0.29 to 0.46)	<0.001	0.66 (0.46 to 0.93)	0.018
O/S-SSI	1702 (9.12)	209 (5.35)	479 (4.97)	0.60 (0.51 to 0.70)	<0.001	0.53 (0.47 to 0.59)	<0.001	0.88 (0.74 to 1.06)	0.172
Colon surgery		()	(<i>'</i> ,	· · · · · · · · · · · · · · · · · · ·		,		· · · · · · · · · · · · · · · · · · ·	
Overall-SSI	2202 (16.79)	241 (8.5)	512 (6.99)	0.52 (0.45 to 0.60)	<0.001	0.40 (0.36 to 0.45)	<0.001	0.77 (0.65 to 0.92)	0.003
S-SSI	813 (6.2)	81 (2.86)	149 (2.03)	0.52 (0.40 to 0.66)	<0.001	0.39 (0.32 to 0.48)	<0.001	0.76 (0.56 to 1.02)	0.065
D-SSI	305 (2.33)	33 (1.16)	56 (0.76)	0.59 (0.41 to 0.87)	0.007	0.37 (0.27 to 0.50)	<0.001	0.62 (0.39 to 0.99)	0.044
O/S-SSI	1084 (8.27)	127 (4.48)	307 (4.19)	0.56 (0.46 to 0.69)	<0.001	0.48 (0.41 to 0.55)	<0.001	0.85 (0.68 to 1.06)	0.147
Rectal surgery	,	()	· · · · ·	· · · · · · · · · · · · · · · · · · ·		,		· · · · · · · · · · · · · · · · · · ·	
Overall-SSI	1188 (21.4)	151 (14.06)	277 (12.02)	0.61 (0.50 to 0.74)	<0.001	0.54 (0.46 to 0.63)	<0.001	0.88 (0.70 to 1.11)	0.280
S-SSI	306 (5.51)	44 (4.1)	64 (2.78)	0.79 (0.56 to 1.11)	0.174	0.56 (0.41 to 0.76)	<0.001	0.71 (0.46 to 1.09)	0.121
D-SSI	264 (4.76)́	25 (2.33́)	41 (1.78)	0.56 (0.36 to 0.87)	0.009	0.41 (0.29 to 0.60)	<0.001	0.74 (0.43 to 1.29)	0.293
O/S-SSI	618 (11.13)	82 (7.64)	172 (7.47)	0.62 (0.48 to 0.80)	<0.001	0.65 (0.54 to 0.79)	<0.001	1.06 (0.79 to 1.42)	0.706

Values are n (%) unless otherwise stated. OR, odds ratio; SSI, surgical site infection; S-SSI, superficial surgical site infection; D-SSI, deep surgical site infection; O/S-SSI, organ-space surgical site infection.

the confidentiality of all patients was maintained (code 20222022). The project was registered at clinicaltrials.gov as NCT06244836.

Institutional review board statement

Data extraction was approved by the Institutional Research Board with code 20166009, and the study was approved by the Clinical Research Ethics Committee of Hospital General de Granollers, with code 2021006. The need for informed consent and the provision of an information sheet were waived because data were routinely collected as part of hospital surveillance and quality improvement.

Results

A total of 32 205 patients were included: 18 664 in the Baseline group, 3908 in the Bundle-1 group and 9633 in the Bundle-2 group. Demographic and surgical characteristics are shown in *Table* 1. After the implementation of IPTW, an assessment of the

balance of the variables among the groups was conducted using a Love Plot (Fig. S2).

SSI rates and bundle compliance

Overall SSI rate decreased steadily over time: from 18.16% in the Baseline group to 10.03% in the Bundle-1 group and 8.19% in the Bundle-2 group (Fig. 1).

In colorectal operations taken together, both bundles significantly decreased overall SSI and its three levels compared with the Baseline group. Specifically, Bundle-2 achieved a 21% reduction in the odds of developing SSI (OR 0.79 (95% c.i. 0.69 to 0.91); P = 0.001) along with a 26% decrease in S-SSI (OR 0.74 (95% c.i. 0.58 to 0.95); P = 0.018) and a 34% reduction in D-SSI (OR 0.66 (95% c.i. 0.46 to 0.93); P = 0.018), compared with Bundle-1. However, Bundle-2 did not show a statistically significant reduction in the likelihood of developing O/S-SSI when compared with Bundle-1 (Table 2).

Table 3 Effect of the individual preventive measures contained in the bundles on overall SSI rates

	Univariate		Multivariate	Multivariate		
Bundle measures	OR (95% c.i.)	Р	OR (95% c.i.)	Р		
Colorectal surgery						
Adequate antibiotic prophylaxis	0.90 (0.83 to 0.98)	0.012	0.91 (0.83 to 0.99)	0.022		
Minimally invasive surgery	0.53 (0.49 to 0.56)	< 0.001	0.62 (0.58 to 0.66)	< 0.001		
Oral antibiotic prophylaxis	0.41 (0.38 to 0.44)	< 0.001	0.68 (0.59 to 0.79)	< 0.001		
Mechanical bowel preparation	0.44 (0.40 to 0.47)	<0.001	0.92 (0.80 to 1.06)	0.237		
Double-ring wound retractor	0.41 (0.38 to 0.45)	< 0.001	0.70 (0.63 to 0.79)	< 0.001		
Maintenance of normothermia	0.45 (0.42 to 0.48)	< 0.001	0.95 (0.82 to 1.08)	0.430		
Adequate hair removal	0.54 (0.48 to 0.61)	< 0.001	1.14 (0.99 to 1.31)	0.074		
2% chlorhexidine in alcohol	0.43 (0.39 to 0.47)	< 0.001	0.75 (0.65 to 0.86)	< 0.001		
Glycaemic control	0.47 (0.43 to 0.52)	< 0.001	0.95 (0.83 to 1.08)	0.418		
Changing of surgical instruments	0.58 (0.42 to 0.77)	< 0.001	1.20 (0.87 to 1.63)	0.243		
Colon surgery						
Adequate antibiotic prophylaxis	0.88 (0.80 to 0.98)	0.018	0.88 (0.80 to 0.98)	0.021		
Minimally invasive surgery	0.48 (0.44 to 0.51)	< 0.001	0.56 (0.52 to 0.61)	< 0.001		
Oral antibiotic prophylaxis	0.34 (0.31 to 0.38)	< 0.001	0.58 (0.49 to 0.68)	< 0.001		
Mechanical bowel preparation	0.38 (0.34 to 0.42)	< 0.001	0.85 (0.72 to 1.01)	0.061		
Double-ring wound retractor	0.40 (0.36 to 0.44)	< 0.001	0.79 (0.68 to 0.91)	0.002		
Maintenance of normothermia	0.43 (0.39 to 0.47)	< 0.001	0.96 (0.81 to 1.13)	0.606		
Adequate hair removal	0.51 (0.44 to 0.59)	<0.001	1.07 (0.90 to 1.27)	0.446		
2% chlorhexidine in alcohol	0.42 (0.38 to 0.47)	<0.001	0.80 (0.67 to 0.95)	0.011		
Glycaemic control	0.45 (0.40 to 0.51)	<0.001	0.92 (0.78 to 1.09)	0.336		
Changing of surgical instruments	0.62 (0.43 to 0.86)	0.006	1.28 (0.88 to 1.81)	0.172		
Rectal surgery						
Adequate antibiotic prophylaxis	0.95 (0.82 to 1.09)	0.449	0.95 (0.83 to 1.11)	0.532		
Minimally invasive surgery	0.63 (0.57 to 0.71)	<0.001	0.72 (0.64 to 0.81)	< 0.001		
Oral antibiotic prophylaxis	0.55 (0.48 to 0.62)	<0.001	0.96 (0.73 to 1.27)	0.757		
Mechanical bowel preparation	0.53 (0.47 to 0.61)	< 0.001	0.83 (0.63 to 1.10)	0.191		
Double-ring wound retractor	0.49 (0.42 to 0.57)	< 0.001	0.72 (0.59 to 0.88)	0.002		
Maintenance of normothermia	0.53 (0.46 to 0.60)	< 0.001	0.88 (0.70 to 1.12)	0.310		
Adequate hair removal	0.63 (0.52 to 0.77)	< 0.001	1.18 (0.93 to 1.49)	0.181		
2% chlorhexidine in alcohol	0.50 (0.43 to 0.59)	<0.001	0.76 (0.61 to 0.96)	0.020		
Glycaemic control	0.56 (0.47 to 0.67)	< 0.001	0.99 (0.79 to 1.25)	0.962		
Changing of surgical instruments	0.55 (0.28 to 0.98)	0.062	0.97 (0.48 to 1.78)	0.931		

OR, odds ratio; SSI, surgical site infection.

Assessing colonic and rectal operations separately: significant reductions in SSI were noted with the application of Bundle-1 and Bundle-2. In colonic procedures, Bundle-2 achieved a 23% reduction in the odds of overall SSI (OR 0.77 (95% c.i. 0.65 to 0.92); P = 0.003) and a significant 38% reduction in D-SSI (OR 0.62 (95% c.i. 0.39 to 0.99); P = 0.044) compared with Bundle-1. However, Bundle-2 did not show statistically significant differences in the odds of developing S-SSI and O/S-SSI compared with Bundle-1. In rectal operations, significant reductions were observed in overall SSI, S-SSI, and D-SSI with Bundle-1 and Bundle-2. However, Bundle-2 did not confer additional benefits in reducing any of the SSI categories, presenting only non-significant differences compared with Bundle-1.

Individual effect of bundle measures on SSI rates

In the univariable analysis of colorectal procedures considered together (*Table 3*), all measures, except adequate antibiotic prophylaxis in rectal surgery, reduced SSI. Multivariable analysis demonstrated that laparoscopy, OAP, use of double-ring wound retractor and skin antisepsis with CHG-alcohol decreased SSI. Similar results were observed in colon surgery, while in the rectum, OAP did not reduce SSI.

For O/S-SSI, laparoscopy, OAP, MBP, double-ring wound retractor and CHG-alcohol were protective factors in colorectal surgery (*Table 4*). In colonic operations, laparoscopy, OAP and

MBP protected from O/S-SSI, but no efficacy was identified for any measure in rectal surgery.

For I-SSI, laparoscopy, OAP, double-ring wound retractor and CHG-alcohol were preventive measures in colorectal and colonic procedures (*Table S3*), while in rectal operations only laparoscopy and wound retractor were independent protective factors.

Secondary outcomes

All measures included in both bundles were adopted with an average adherence rate of 70–80%, which increased over time (*Table S4*). Compliance with five or more measures increased over the course of the study and was associated with a reduction in the SSI rate (Fig. 2).

LOS fell significantly over time, from 7 in the Baseline group to 6 and 5 days for Bundle-1 and Bundle-2 respectively (P < 0.001) (*Table 5*). There was no difference in the median time to SSI development in the study interval, while more SSIs were diagnosed after discharge (from 29 to 40%) with the application of bundles.

The mortality rate fell over time, from 1.4% to 0.59% and 0.6% at Baseline, Bundle-1 and Bundle-2 (P < 0.001) respectively. Measures added in Bundle-2 did not reduce the mortality rate.

The microorganisms causing SSI in colorectal surgery were variable throughout the study. In the O/S-SSI category (*Table 6*), Bundle-1 led to a higher isolation of Gram-positive bacteria (mainly due to an increase of *Enterococcus faecalis* and

Table 4 Effect of the individual preventive measures contained in the bundles on O/S-SSI rates

	Univariate		Multivariate		
Bundle measures	OR (95% c.i.)	Р	OR (95% c.i.)	Р	
Colorectal surgery					
Adequate antibiotic prophylaxis	0.89 (0.80 to 1.00)	0.046	0.90 (0.81 to 1.01)	0.061	
Minimally invasive surgery	0.69 (0.63 to 0.75)	<0.001	0.78 (0.72 to 0.85)	< 0.001	
Oral antibiotic prophylaxis	0.53 (0.47 to 0.58)	<0.001	0.82 (0.68 to 0.98)	0.029	
Mechanical bowel preparation	0.53 (0.48 to 0.59)	<0.001	0.82 (0.69 to 0.99)	0.036	
Double-ring wound retractor	0.54 (0.49 to 0.60)	<0.001	0.82 (0.71 to 0.95)	0.010	
Maintenance of normothermia	0.56 (0.51 to 0.61)	<0.001	0.98 (0.82 to 1.16)	0.789	
Adequate hair removal	0.65 (0.56 to 0.75)	<0.001	1.13 (0.94 to 1.35)	0.177	
2% chlorhexidine in alcohol	0.53 (0.48 to 0.60)	<0.001	0.78 (0.66 to 0.93)	0.006	
Glycaemic control	0.58 (0.51 to 0.65)	<0.001	0.94 (0.79 to 1.12)	0.501	
Changing of surgical instruments	0.61 (0.40 to 0.89)	0.016	1.00 (0.64 to 1.48)	0.992	
Colon surgery					
Adequate antibiotic prophylaxis	0.88 (0.76 to 1.01)	0.062	0.88 (0.77 to 1.01)	0.067	
Minimally invasive surgery	0.60 (0.54 to 0.67)	<0.001	0.69 (0.62 to 0.77)	< 0.001	
Oral antibiotic prophylaxis	0.46 (0.40 to 0.53)	<0.001	0.74 (0.60 to 0.93)	0.008	
Mechanical bowel preparation	0.46 (0.40 to 0.52)	<0.001	0.73 (0.59 to 0.91)	0.005	
Double-ring wound retractor	0.53 (0.47 to 0.60)	<0.001	0.94 (0.78 to 1.14)	0.516	
Maintenance of normothermia	0.53 (0.47 to 0.60)	<0.001	0.96 (0.77 to 1.20)	0.749	
Adequate hair removal	0.61 (0.51 to 0.73)	<0.001	1.07 (0.86 to 1.34)	0.536	
2% chlorhexidine in alcohol	0.52 (0.45 to 0.60)	<0.001	0.85 (0.68 to 1.07)	0.164	
Glycaemic control	0.54 (0.46 to 0.63)	<0.001	0.86 (0.69 to 1.07)	0.178	
Changing of surgical instruments	0.76 (0.48 to 1.14)	0.217	1.26 (0.78 to 1.93)	0.313	
Rectal surgery	· · · · · · · · · · · · · · · · · · ·				
Adequate antibiotic prophylaxis	0.94 (0.78 to 1.14)	0.518	0.95 (0.79 to 1.15)	0.574	
Minimally invasive surgery	0.87 (0.76 to 1.01)	0.066	0.96 (0.83 to 1.12)	0.624	
Oral antibiotic prophylaxis	0.66 (0.55 to 0.77)	< 0.001	0.95 (0.67 to 1.35)	0.768	
Mechanical bowel preparation	0.65 (0.55 to 0.76)	< 0.001	0.82 (0.57 to 1.16)	0.268	
Double-ring wound retractor	0.63 (0.52 to 0.76)	<0.001	0.84 (0.66 to 1.09)	0.189	
Maintenance of normothermia	0.66 (0.56 to 0.77)	< 0.001	0.95 (0.70 to 1.28)	0.729	
Adequate hair removal	0.77 (0.60 to 0.97)	0.031	1.14 (0.85 to 1.53)	0.378	
2% chlorhexidine in alcohol	0.62 (0.51 to 0.76)	<0.001	0.77 (0.58 to 1.02)	0.069	
Glycaemic control	0.72 (0.58 to 0.88)	0.002	1.10 (0.83 to 1.47)	0.498	
Changing of surgical instruments	0.28 (0.07 to 0.75)	0.030	0.39 (0.09 to 1.05)	0.110	

OR, odds ratio; O/S-SSI, organ-space surgical site infection.



Fig. 2 Relationship between the percentage of compliance with five or more bundle measures and overall SSI rate O-SSI, overall surgical site infection.

Table 5 Secondary outcomes of the study

				Baseline group (ref.) versus Bundle-1		Baseline group (ref.) versus Bundle-2		Bundle-1 (ref.) versus Bundle-2	
Outcomes	Baseline group	Bundle-1	Bundle-2		Р		Р		Р
Colorectal surgery									
LOS (days), median (i.q.r.)*	7 (5–11)	6 (4–8)	5 (4–8)	1	<0.001	2	<0.001	1	<0.001
Days to SSI, median (i.q.r.)*	7 (5–12)	8 (5–13)	8 (4–13.5)	1	0.180	1	0.466	0	0.561
30-day mortality rate, n (%)†	261 (1.4)	23 (0.59)	58 (0.6)	0.53 (0.34 to 0.83)	0.005	0.51 (0.37 to 0.71)	<0.001	0.97 (0.58 to 1.64)	0.916
Postdischarge SSI, n (%)†	937 (29 53)	105 (35-23)	138 (40 47)	1.24 (0.96 to 1.62)	0.105	1.54 (1.2 to 1.97)	<0.001	1.24 (0.88 to 1.74)	0.227
Colon surgery	(29.99)	(33.23)	(10.17)						
LOS (days), median (i.g.r.)*	7 (5–10)	6 (4–8)	5 (4-7)	1	< 0.001	2	< 0.001	1	< 0.001
Days to SSL median (i.g.r.)*	7 (5–11)	7 (5–12)	7 (4–12)	0	0.178	0	0.234	0	0.745
30-day mortality rate, n (%)†	203	18 (0.64)	50 (0.68)	0.55 (0.33 to 0.91)	0.019	0.56 (0.39 to 0.8)	0.001	1.02 (0.57 to 1.82)	0.946
Postdischarge SSI, n (%)†	592 (28.82)	69 (36.7)	82 (39.23)	1.34 (0.96 to 1.85)	0.082	1.49 (1.08 to 2.04)	0.014	1.11 (0.72 to 1.72)	0.63
Rectal Surgery	· · ·								
LOS (days), median (i.q.r.)*	8 (6–13)	6 (5–10)	6 (4–9)	2	<0.001	2	<0.001	0	<0.001
Days to SSI, median (i.g.r.)*	9 (5–14)	9 (5–14.5)	9 (5–16)	0	0.815	0	0.798	0	0.758
30-day mortality rate, n (%)+	58 (1.04)	5 (0.47)	8 (0.35)	0.46 (0.17 to 1.24)	0.123	0.28 (0.13 to 0.59)	< 0.001	0.6 (0.18 to 1.98)	0.402
Postdischarge SSI, n (%)†	345 (30.83)	36 (32.7 [°] 3)	56 (42.42)	1.1 (0.7 to 1.72)	0.69	1.67 (1.11 to 2.52)	0.014	1.53 (0.85 to 2.73)	0.154

*Absolute difference in medians; †OR (95% c.i.) in comparative columns. i.q.r., interquartile range; LOS, duration of stay; SSI, surgical site infection.

Enterococcus faecium), and yeasts (Candida spp.), and decreased Gram-negative bacteria, specifically Escherichia coli, Pseudomonas spp. and anaerobes (Bacteroides spp.), compared with the Baseline group. Bundle-2 added some benefits to Bundle-1, reducing Bacteroides spp. Microorganisms causing I-SSI did not change with Bundle-1 in comparison to Baseline (Table 6). However, Bundle-2 was associated with an increase in Gram-positive (mainly methicillin-susceptible Staphylococcus aureus) and a reduction in Gram-negative bacteria (Escherichia coli) and anaerobes.

Discussion

This prospective multicentre cohort study demonstrated a 50% reduction in overall SSI after the implementation of two sequential sets of bundles, from 18.16% to 8.19%. These results were recorded by different hospitals and ICTs, although it is important to note that this was probably made possible by leveraging a well established nationwide surveillance system for healthcare-associated infections. Similar results have been reported previously^{9,12,26-28}.

The addition of new measures (from a six-measure protocol in Bundle-1 to a 10-measure protocol in Bundle-2) within a national SSI surveillance programme increased compliance. Adherence above 70% is favourable compared with previous studies reporting adherence rates between 50 and 70%. These two packages were successfully introduced in less than a year, building on a well established national surveillance system for health-related infections in a large network of hospitals. The application of bundles in similar multicentre collaborative settings has shown that quality improvement projects can be easier to implement in these environments²⁹.

Although bundles with a large number of measures may face greater challenges in terms of implementation³⁰, this study corroborates two previous meta-analyses^{9,17} in demonstrating that bundles that include 10 or more measures implemented

correctly can lead to the greatest reduction in SSI. In order to achieve this, involvement of stakeholders in its implementation is crucial, giving feedback on the results and taking advantage of their new ideas to improve compliance³⁰.

Application of Bundle-1 and Bundle-2 reduced not only incisional SSI but O/S-SSI as well. Previously published colorectal bundles have been found to be effective in reducing I-SSI but did not improve O/S-SSI^{12,28}. These results are relevant because the effects of O/S-SSI are more impactful compared with I-SSI in terms of LOS, 30-day mortality rate (from 2% without O/S-SSI to 24% with it)³¹ and reducing long-term survival³².

However, in this cohort the effect of the bundles was different for I-SSIs and O/S-SSIs: the addition of the four extra measures in Bundle-2 only reduced I-SSIs and did not significantly influence O/S-SSIs. These differences may be explained as Bundle-1 measures were specifically chosen to reduce not just overall SSI and O/S-SSIs in colorectal surgery, whereas the Bundle-2 measures were added in the surveillance programme with the aim of reducing the SSI rate in all types of surgical procedures and were perhaps more targeted at I-SSIs. O/S-SSI has traditionally been related to anastomotic leakage, which is assumed to be related to technical factors in the construction of the anastomosis, such as ensuring a good blood supply and the absence of tension, and the creation of a protective stoma in high-risk groups^{33,34}. In addition, recent research has highlighted other aspects such as the diversity and composition of the colonic microbiota or intraoperative resuscitation as contributing factors^{35–37}. Several studies demonstrated in animal models that alteration of the gut microbiome involving the growth of specific microorganisms, such as Pseudomonas aeruginosa and Enterococcus spp., could lead to tissue destruction and anastomotic leakage^{38,39}.

In contrast to most studies, this study analysed colon and rectal surgery separately as these two types of surgery have different SSI risk factors, intraoperative technical factors and postoperative management^{40,41}. Although the bundles reduced SSI overall, when analysing the individual effect of the items

Table 6 Microorganisms causing O/S-SSI and I-SSI throughout the study

Organisms isolated in O/S-SSI

Organisms Overall Baseline group Bundle-1 Bundle-2 Baseline group (ref.) versus Bundle 1 Baseline group (ref.) versus Bundle 2 Bundle-1 (ref.) versus Bundle 2 Number 2910 2117 245 548 559 59 59 164 (7.7) 34 (13.9) 61 (11.1) 0.002 0.015 0.228 518 518 517 0.031 0.616 517 0.211 0.031 0.616 518 517 0.212 0.68 7 1.39 1.000 0.827 0.729 MRSA 13 (0.4) 9 (0.4) 2 (0.8) 2 (0.4) 0.319 1.000 0.591 MS54 1.361 1.000 0.591 MSA 0.216 1.000 0.591 MS64 1.361 <th>-</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	-							
Number29102117245548Gram-positive bacteria632 (21.7)413 (19.5)75 (30.6)144 (26.3)<0.001	Organisms	Overall	Baseline group	Bundle-1	Bundle-2	Baseline group (ref.) versus Bundle 1	Baseline group (ref.) versus Bundle 2	Bundle-1 (ref.) versus Bundle 2
Gram-positive bacteria 632 (21.7) 413 (19.5) 75 (30.6) 144 (26.3) <0.001 0.021 Enterococcus faecalis 259 (8.9) 164 (7.7) 34 (13.9) 61 (11.1) 0.002 0.015 0.288 Enterococcus faecium 234 (8.0) 151 (7.1) 28 (11.4) 55 (10.0) 0.021 0.031 0.616 Enterococcus spp. 33 (1.1) 27 (1.3) 2 (0.8) 4 (0.7) 0.762 0.374 1.000 Streptococcus spp. 34 (1.2) 25 (1.2) 2 (0.8) 7 (1.3) 1.000 0.827 0.729 MRSA 13 (0.4) 9 (0.4) 2 (0.8) 2 (0.4) 0.319 1.000 0.591 MSSA 29 (1.0) 20 (0.9) 5 (2.0) 4 (0.7) 0.173 0.802 0.144 Other GPB 93 (3.2) 62 (2.9) 9 (3.7) 22 (4.0) 0.551 0.216 1.000 Gram-negative bacteria 1361 (46.8) 1030 (48.7) 106 (43.3) 225 (41.1) 0.120 0.002 0.586 Esc	Number	2910	2117	245	548			
Enterococcus faecalis 259 (8.9) 164 (7.7) 34 (13.9) 61 (11.1) 0.002 0.015 0.288 Enterococcus faecium 234 (8.0) 151 (7.1) 28 (11.4) 55 (10.0) 0.021 0.031 0.616 Enterococcus spp. 33 (1.1) 27 (1.3) 2 (0.8) 4 (0.7) 0.762 0.374 1.000 Streptococcus spp. 34 (1.2) 25 (1.2) 2 (0.8) 7 (1.3) 1.000 0.827 0.729 MRSA 13 (0.4) 9 (0.4) 2 (0.8) 2 (0.4) 0.319 1.000 0.591 MSSA 29 (1.0) 20 (0.9) 5 (2.0) 4 (0.7) 0.173 0.802 0.144 Other GPB 93 (3.2) 62 (2.9) 9 (3.7) 22 (4.0) 0.551 0.216 1.000 Gram-negative bacteria 1361 (46.8) 1030 (48.7) 106 (43.3) 225 (41.1) 0.125 <0.001 0.093 Klebsiella spp. 5 (0.2) 1 (0.0) 1 (0.4) 3 (0.5) 0.197 0.029 1.000 Pseudomonas spp. 161 (5.5) 128 (6.0) 5 (2.0) 28 (5.1) 0.008 0.475 0.53 Enterobacter spp. 13 (0.4) 9 (0.4) 1 (0.4) 3 (0.5) 1.000 0.720 1.000 Other GNB 468 (16.1) 325 (15.4) 45 (18.4) 98 (17.9) 0.227 0.149 0.920 Anaerobes 94 (3.2) 77 (3.6) 9 (3.7) 8 (1.5) 1.000 0.002 0.011	Gram-positive bacteria	632 (21.7)	413 (19.5)	75 (30.6)	144 (26.3)	<0.001	0.001	0.229
Enterococcus faecium234 (8.0)151 (7.1)28 (11.4)55 (10.0)0.0210.0310.616Enterococcus spp.33 (1.1)27 (1.3)2 (0.8)4 (0.7)0.7620.3741.000Streptococcus spp.34 (1.2)25 (1.2)2 (0.8)7 (1.3)1.0000.8270.729MRSA13 (0.4)9 (0.4)2 (0.8)2 (0.4)0.3191.0000.591MSSA29 (1.0)20 (0.9)5 (2.0)4 (0.7)0.1730.8020.144Other GPB93 (3.2)62 (2.9)9 (3.7)22 (4.0)0.5510.2161.000Gram-negative bacteria1361 (46.8)1030 (48.7)106 (43.3)225 (41.1)0.1200.0020.586Escherichia coli714 (24.5)567 (26.8)54 (22.0)93 (17.0)0.125<0.001	Enterococcus faecalis	259 (8.9)	164 (7.7)	34 (13.9)	61 (11.1)	0.002	0.015	0.288
Enterococcus spp.33 (1.1)27 (1.3)2 (0.8)4 (0.7)0.7620.3741.000Streptococcus spp.34 (1.2)25 (1.2)2 (0.8)7 (1.3)1.0000.8270.729MRSA13 (0.4)9 (0.4)2 (0.8)2 (0.4)0.3191.0000.591MSSA29 (1.0)20 (0.9)5 (2.0)4 (0.7)0.1730.8020.144Other GPB93 (3.2)62 (2.9)9 (3.7)22 (4.0)0.5510.2161.000Gram-negative bacteria1361 (46.8)1030 (48.7)106 (43.3)225 (41.1)0.1200.0020.586Escherichia coli714 (24.5)567 (26.8)54 (22.0)93 (17.0)0.125<0.001	Enterococcus faecium	234 (8.0)	151 (7.1)	28 (11.4)	55 (10.0)	0.021	0.031	0.616
Streptococcus spp. $34(1.2)$ $25(1.2)$ $2(0.8)$ $7(1.3)$ 1.000 0.827 0.729 MRSA $13(0.4)$ $9(0.4)$ $2(0.8)$ $2(0.4)$ 0.319 1.000 0.591 MSA $29(1.0)$ $20(0.9)$ $5(2.0)$ $4(0.7)$ 0.173 0.802 0.144 Other GPB $93(3.2)$ $62(2.9)$ $9(3.7)$ $22(4.0)$ 0.551 0.216 1.000 Gram-negative bacteria $1361(46.8)$ $1030(48.7)$ $106(43.3)$ $225(41.1)$ 0.120 0.002 0.586 Escherichia coli $714(24.5)$ $567(26.8)$ $54(22.0)$ $93(17.0)$ 0.125 <0.001 0.093 Klebsiella spp. $5(0.2)$ $1(0.0)$ $1(0.4)$ $3(0.5)$ 0.197 0.029 1.000 Pseudomonas spp. $161(5.5)$ $128(6.0)$ $5(2.0)$ $28(5.1)$ 0.008 0.475 0.533 Enterobacter spp. $13(0.4)$ $9(0.4)$ $1(0.4)$ $3(0.5)$ 1.000 0.720 1.000 Other GNB $468(16.1)$ $325(15.4)$ $45(18.4)$ $98(17.9)$ 0.227 0.149 0.920 Anaerobes $94(3.2)$ $77(3.6)$ $9(3.7)$ $8(1.5)$ 1.000 0.002 0.062 Bacteroides spp. $74(2.5)$ $62(2.9)$ $8(3.3)$ $4(0.7)$ 0.693 0.002 0.011 Clostridium spp. $16(0.5)$ $13(0.6)$ $1(0.4)$ $2(0.4)$ 1.000 0.750 1.000 Yeasts $103(3.5)$ $54(2.6)$ $9(3.7)$ </td <td>Enterococcus spp.</td> <td>33 (1.1)</td> <td>27 (1.3)</td> <td>2 (0.8)</td> <td>4 (0.7)</td> <td>0.762</td> <td>0.374</td> <td>1.000</td>	Enterococcus spp.	33 (1.1)	27 (1.3)	2 (0.8)	4 (0.7)	0.762	0.374	1.000
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Streptococcus spp.	34 (1.2)	25 (1.2)	2 (0.8)	7 (1.3)	1.000	0.827	0.729
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	MRSA	13 (0.4)	9 (0.4)	2 (0.8)	2 (0.4)	0.319	1.000	0.591
Other GPB93 (3.2) 62 (2.9) 9 (3.7) 22 (4.0) 0.5510.2161.000Gram-negative bacteria1361 (46.8) 1030 (48.7) 106 (43.3) 225 (41.1) 0.1200.0020.586Escherichia coli714 (24.5) 567 (26.8) 54 (22.0) 93 (17.0) 0.125<0.0010.093Klebsiella spp.5 (0.2) 1 (0.0) 1 (0.4) 3 (0.5) 0.1970.0291.000Pseudomonas spp.161 (5.5) 128 (6.0) 5 (2.0) 28 (5.1) 0.0080.4750.053Enterobacter spp.13 (0.4) 9 (0.4) 1 (0.4) 3 (0.5) 1.0000.7201.000Other GNB468 (16.1) 325 (15.4) 45 (18.4) 98 (17.9) 0.2270.1490.920Anaerobes94 (3.2) 77 (3.6) 9 (3.7) 8 (1.5) 1.0000.0020.062Bacteroides spp.74 (2.5) 62 (2.9) 8 (3.3) 4 (0.7) 0.6930.0020.011Clostridium spp.16 (0.5) 13 (0.6) 1 (0.4) 2 (0.4) 1.0000.7501.000Yeasts103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294<0.0010.055Candida spp.103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294<0.0010.055	MSSA	29 (1.0)	20 (0.9)	5 (2.0)	4 (0.7)	0.173	0.802	0.144
Gram-negative bacteria1361 (46.8)1030 (48.7)106 (43.3)225 (41.1)0.1200.0020.586Escherichia coli714 (24.5)567 (26.8)54 (22.0)93 (17.0)0.125<0.0010.093Klebsiella spp.5 (0.2)1 (0.0)1 (0.4)3 (0.5)0.1970.0291.000Pseudomonas spp.161 (5.5)128 (6.0)5 (2.0)28 (5.1)0.0080.4750.053Enterobacter spp.13 (0.4)9 (0.4)1 (0.4)3 (0.5)1.0000.7201.000Other GNB468 (16.1)325 (15.4)45 (18.4)98 (17.9)0.2270.1490.920Anaerobes94 (3.2)77 (3.6)9 (3.7)8 (1.5)1.0000.0020.011Clostridium spp.16 (0.5)13 (0.6)1 (0.4)2 (0.4)1.0000.7501.000Yeasts103 (3.5)54 (2.6)9 (3.7)40 (7.3)0.294<0.0010.055Candida spp.103 (3.5)54 (2.6)9 (3.7)40 (7.3)0.294<0.0010.055	Other GPB	93 (3.2)	62 (2.9)	9 (3.7)	22 (4.0)	0.551	0.216	1.000
Escherichia coli714 (24.5)567 (26.8)54 (22.0)93 (17.0)0.125<0.0010.093Klebsiella spp.5 (0.2)1 (0.0)1 (0.4)3 (0.5)0.1970.0291.000Pseudomonas spp.161 (5.5)128 (6.0)5 (2.0)28 (5.1)0.0080.4750.053Enterobacter spp.13 (0.4)9 (0.4)1 (0.4)3 (0.5)1.0000.7201.000Other GNB468 (16.1)325 (15.4)45 (18.4)98 (17.9)0.2270.1490.920Anaerobes94 (3.2)77 (3.6)9 (3.7)8 (1.5)1.0000.0090.062Bacteroides spp.74 (2.5)62 (2.9)8 (3.3)4 (0.7)0.6930.0020.011Clostridium spp.16 (0.5)13 (0.6)1 (0.4)2 (0.4)1.0000.7501.000Yeasts103 (3.5)54 (2.6)9 (3.7)40 (7.3)0.294<0.001	Gram-negative bacteria	1361 (46.8)	1030 (48.7)	106 (43.3)	225 (41.1)	0.120	0.002	0.586
Klebsiella spp.5 (0.2)1 (0.0)1 (0.4)3 (0.5)0.1970.0291.000Pseudomonas spp.161 (5.5)128 (6.0)5 (2.0)28 (5.1)0.0080.4750.053Enterobacter spp.13 (0.4)9 (0.4)1 (0.4)3 (0.5)1.0000.7201.000Other GNB468 (16.1)325 (15.4)45 (18.4)98 (17.9)0.2270.1490.920Anaerobes94 (3.2)77 (3.6)9 (3.7)8 (1.5)1.0000.0090.062Bacteroides spp.74 (2.5)62 (2.9)8 (3.3)4 (0.7)0.6930.0020.011Clostridium spp.16 (0.5)13 (0.6)1 (0.4)2 (0.4)1.0000.7501.000Yeasts103 (3.5)54 (2.6)9 (3.7)40 (7.3)0.294<0.001	Escherichia coli	714 (24.5)	567 (26.8)	54 (22.0)	93 (17.0)	0.125	< 0.001	0.093
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Klebsiella spp.	5 (0.2)	1 (0.0)	1 (0.4)	3 (0.5)	0.197	0.029	1.000
Enterobacter spp.13 (0.4)9 (0.4)1 (0.4)3 (0.5)1.0000.7201.000Other GNB468 (16.1)325 (15.4)45 (18.4)98 (17.9)0.2270.1490.920Anaerobes94 (3.2)77 (3.6)9 (3.7)8 (1.5)1.0000.0090.062Bacteroides spp.74 (2.5)62 (2.9)8 (3.3)4 (0.7)0.6930.0020.011Clostridium spp.16 (0.5)13 (0.6)1 (0.4)2 (0.4)1.0000.7501.000Yeasts103 (3.5)54 (2.6)9 (3.7)40 (7.3)0.294<0.001	Pseudomonas spp.	161 (5.5)	128 (6.0)	5 (2.0)	28 (5.1)	0.008	0.475	0.053
Other GNB 468 (16.1) 325 (15.4) 45 (18.4) 98 (17.9) 0.227 0.149 0.920 Anaerobes 94 (3.2) 77 (3.6) 9 (3.7) 8 (1.5) 1.000 0.009 0.062 Bacteroides spp. 74 (2.5) 62 (2.9) 8 (3.3) 4 (0.7) 0.693 0.002 0.011 Clostridium spp. 16 (0.5) 13 (0.6) 1 (0.4) 2 (0.4) 1.000 0.750 1.000 Yeasts 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055 Candida spp. 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055	Enterobacter spp.	13 (0.4)	9 (0.4)	1 (0.4)	3 (0.5)	1.000	0.720	1.000
Anaerobes 94 (3.2) 77 (3.6) 9 (3.7) 8 (1.5) 1.000 0.009 0.062 Bacteroides spp. 74 (2.5) 62 (2.9) 8 (3.3) 4 (0.7) 0.693 0.002 0.011 Clostridium spp. 16 (0.5) 13 (0.6) 1 (0.4) 2 (0.4) 1.000 0.750 1.000 Yeasts 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055 Candida spp. 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001	Other GNB	468 (16.1)	325 (15.4)	45 (18.4)	98 (17.9)	0.227	0.149	0.920
Bacteroides spp. 74 (2.5) 62 (2.9) 8 (3.3) 4 (0.7) 0.693 0.002 0.011 Clostridium spp. 16 (0.5) 13 (0.6) 1 (0.4) 2 (0.4) 1.000 0.750 1.000 Yeasts 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055 Candida spp. 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001	Anaerobes	94 (3.2)	77 (3.6)	9 (3.7)	8 (1.5)	1.000	0.009	0.062
Clostridium spp. 16 (0.5) 13 (0.6) 1 (0.4) 2 (0.4) 1.000 0.750 1.000 Yeasts 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055 Candida spp. 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055	Bacteroides spp.	74 (2.5)	62 (2.9)	8 (3.3)	4 (0.7)	0.693	0.002	0.011
Yeasts 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055 Candida spp. 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001	Clostridium spp.	16 (0.5)	13 (0.6)	1 (0.4)	2 (0.4)	1.000	0.750	1.000
Candida spp. 103 (3.5) 54 (2.6) 9 (3.7) 40 (7.3) 0.294 <0.001 0.055	Yeasts	103 (3.5)	54 (2.6)	9 (3.7)	40 (7.3)	0.294	< 0.001	0.055
	Candida spp.	103 (3.5)	54 (2.6)	9 (3.7)	40 (7.3)	0.294	<0.001	0.055

Organisms isolated in incisional-SSI

Organisms	Overall	Baseline group	Bundle-1	Bundle-2	Baseline group (ref.) versus Bundle 1	Baseline group (ref.) versus Bundle 2	Bundle-1 (ref.) versus Bundle 2
Number	2538	1979	217	342			
Gram-positive bacteria	536 (21.1)	390 (19.7)	49 (22.6)	97 (28.4)	0.325	< 0.001	0.139
Enterococcus faecalis	214 (8.4)	159 (8.0)	24 (11.1)	31 (9.1)	0.153	0.522	0.468
Enterococcus faecium	76 (3.0) [´]	53 (2.7) [°]	6 (2.8)	17 (5.0)	0.827	0.038	0.275
Enterococcus spp.	19 (0.7)	18 (0.9)	1 (0.5)	0 (0.0)	1.000	0.094	0.388
Streptococcus spp.	42 (1.7)	38 (1.9)	0 (0.0)	4 (1.2)	0.028	0.508	0.161
MRŚA	20 (0.8)	15 (0.8)	1 (0.5)	4 (1.2)	1.000	0.509	0.653
MSSA	106 (4.2)	64 (3.2)	14 (6.5)	28 (8.2)	0.031	<0.001	0.512
Other GPB	207 (8.2)	145 (7.3)	17 (7.8)	45 (13.2)	0.784	0.001	0.054
Gram-negative bacteria	1327 (52.3)	1051 (53.1)	118 (54.4)	158 (46.2)	0.774	0.019	0.068
Escherichia coli	720 (28.4)	596 (30.1)	53 (24.4)	71 (20.8)	0.085	<0.001	0.347
Klebsiella spp.	1 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)	1.000	0.147	1.000
Pseudomonas spp.	176 (6.9)	129 (6.5)	22 (10.1)	25 (7.3)	0.064	0.558	0.274
Enterobacter spp.	8 (0.3)	7 (0.4)	0 (0.0)	1 (0.3)	1.000	1.000	1.000
Other GNB	422 (16.6)	319 (16.1)	43 (19.8)	60 (17.5)	0.177	0.526	0.504
Anaerobes	98 (3.9)	85 (4.3)	8 (3.7)	5 (1.5)	0.859	0.009	0.147
Bacteroides spp.	93 (3.7)	82 (4.1)	6 (2.8)	5 (1.5)	0.464	0.013	0.352
Clostridium spp.	4 (0.2)	3 (0.2)	1 (0.5)	0 (0.0)	0.341	1.000	0.388
Yeasts	22 (0.9)	17 (0.9)	1 (0.5)	4 (1.2)	1.000	0.537	0.653
Candida spp.	22 (0.9)	17 (0.9)	1 (0.5)	4 (1.2)	1.000	0.537	0.653

Values are n (%) unless otherwise indicated. O/S-SSI, organ/space-surgical site infection; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; GPB, Gram-positive bacteria; GNB, Gram-negative bacteria.

included, the multivariable study detected differences between colon and rectal surgery. In colonic surgery, the protective factors for I-SSI were the use of laparoscopy, OAP, double-ring wound retractor and CHG-alcohol skin antisepsis, while in rectal surgery only laparoscopy and double-ring wound retractor were significant.

In cases of O/S-SSI, laparoscopy, OAP and MBP were beneficial in colon surgery, but none of the factors were protective in rectal surgery. Notably, no single protective factor was found for O/S-SSI in rectal surgery. The more demanding technical aspects of this surgery, such as the potential need for neoadjuvant radiotherapy, the proximity of the sphincters, the high-risk distal anastomoses and the narrow pelvis may counteract the positive effect of the measures included in the bundles^{42–44}. A study of patients analysing risk factors and outcomes of O/S-SSI after elective colon and rectal surgery showed that the overall O/S-SSI rates were higher in rectal surgery. Patients were younger but had a higher proportion of malignancy, received chemoradiotherapy more frequently and had a longer duration of surgery. Surgical techniques were also different, with a higher proportion of patients requiring stomas⁴⁵.

Р

Р

As for the maintenance of normothermia, the hypothesis was that this would achieve better intraoperative homeostasis, as previously demonstrated with other haemodynamic parameters³⁶. This would reduce anastomotic leakage and, in turn, O/S-SSI, but this was not demonstrated as a protective effect. This apparent lack of any benefit in maintaining normothermia can be attributed to the fact that the difference in temperature between the SSI and non-SSI patient groups was only 0.1°C. As all patients are currently undergoing perioperative warming, the temperature differences are marginal and do not reach statistical significance as a preventive measure of O/S-SSI.

It is clear that during the study interval there have been advances in care practices that may have acted as confounding factors in the evaluation of the particular interventions applied by the programme. The most important of these is the widespread introduction of the laparoscopic technique in colorectal surgery. Laparoscopy has been shown to reduce overall and incisional SSIs, although most studies find no effect on O/S-SSIs^{46,47}. Instead, in this series, the stepwise introduction of laparoscopy acted as a significant preventive factor not only for general and incisional SSIs, but also for O/S-SSIs, although to a lesser extent.

Compliance with well founded evidence-based measures and the fall in SSI are associated with improvements in LOS and the mortality rate (from 1.4% to 0.6%). As a result of shorter LOS, more SSIs were detected after discharge, a circumstance that should encourage the design of methods to detect infectious complications before discharge, especially O/S-SSI. Several studies have included C-reactive protein (CRP) as a guide for early detection of anastomotic leaks. This assessment if properly applied in Enhance Recovery After Surgery protocols is important for early and safe patient discharge^{48–53}. Three meta-analyses concluded that with CRP levels below 150 mg/l on postoperative day 3, anastomotic leakage can be ruled out in 97% of patients^{54–56}. In addition, it has recently been shown that a CRP-based protocol in elective colorectal surgery provides better results in terms of anastomotic salvage⁵⁷.

Although we found OAP to be successful in reducing SSIs, its use has probably led to a change in the microorganisms isolated from SSIs after colorectal surgery. There was a significant reduction in Gram-negative bacteria but an increase in Gram-positive bacteria, mainly *Enterococcus* spp., with a substantial increase in *E. faecium* and yeasts in accordance with previous studies⁵⁸⁻⁶⁰. In experimental animal studies, oral antibiotics (for example neomycin) changed the diversity of the gut microbiota and increased the presence of potentially pathogenic genera such as *Enterococcus*⁵⁴. This information should be considered when elderly patients with significant morbidities develop severe SSI after colorectal surgery; in these cases, perhaps empirical antibiotic treatment covering these aetiologies should be considered.

This study has several limitations. First, as this is based on population-based databases, information on other factors that might influence the occurrence of SSI, such as body mass index, smoking and co-morbidities, or on surgical factors such as the type of anastomosis or the occurrence of anastomotic leakage, was not available. It is also possible that some of the recommendations introduced later in the bundles, such as changing instruments before wound closure, for example, were already implemented at some participating hospitals, but it cannot be established which ones, or to what extent. Additionally, over the long time interval analysed in the study there have been changes in clinical practice (for instance, the increasing use of laparoscopy) which may have influenced the results.

Collaborators

VINCat Colorectal Surveillance Team

Domenico Fraccalvieri (Department of Surgery, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain); Ana Abad-Torrent (Department of Anaesthesiology, Hospital Universitari Vall d'Hebrón, Barcelona, Spain); Alejandro Solís-Peña (Department of Surgery, Hospital Universitari Vall d'Hebrón, Barcelona, Spain); Mireia Puig-Asensio (Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain); Lucrecia López (Infection Control Team, Hospital de Moisès Broggi, Sant Joan Despí, Spain); Marta Piriz (Infection Control Team, Hospital Universitari Sant Pau, Barcelona, Spain); Mercè Hernández (Department of Surgery, Hospital Universitari Parc Taulí, Sabadell, Spain); Dolors Castellana (Hospital Universitari Arnau de Vilanova, Lleida, Spain); Elisa Montiu González (Hospital Universitari Arnau de Vilanova, Lleida, Spain); Graciano García Pardo (Hospital Universitari Joan XXIII, Tarragona, Spain); Francesc Feliu Villaró (Hospital Universitari Joan XXIII, Tarragona, Spain); Josep Rebull Fatsini (Hospital Verge de la Cinta, Tortosa, Spain); Marie France Domènech Spaneda (Hospital Verge de la Cinta, Tortosa, Spain); Marta Conde Galí (Hospital Universitari Dr. Josep Trueta, Girona, Spain); Anna Oller Pérez-Hita (Hospital Universitari Dr. Josep Trueta, Girona, Spain); Lydia Martín (Hospital de Viladecans, Viladecans, Spain); Ana Lerida (Hospital de Viladecans, Viladecans, Spain); Sebastiano Biondo (Hospital Universitari de Bellvitge, L'Hospitalet de LLobregat, Spain); Emilio Jiménez Martínez (Hospital Universitari de Bellvitge, L'Hospitalet de LLobregat, Spain); Nieves Sopena Galindo (Hospital Universitari Germans Tries i Pujol, Badalona, Spain); Ignasi Camps Ausàs (Hospital Universitari Germans Tries i Pujol, Badalona, Spain); Carmen Ferrer (Hospital Universitari Vall d'Hebron, Barcelona, Spain); Luis Salas (Hospital Universitari Vall d'Hebron, Barcelona, Spain); Rafael Pérez Vidal (Althaia Xarxa Assistencial, Manresa, Spain); Dolors Mas Rubio (Althaia Xarxa Assistencial, Manresa, Spain); Irene García de la Red (Hospital HM Delfos, Barcelona, Spain); Mª Angels Iruela Castillo (Clínica Girona, Girona, Spain); Eva Palau i Gil (Clínica Girona, Girona, Spain); José Antonio Martínez (Hospital Clínic de Barcelona, Barcelona, Spain); M. Blanca Torralbo Navarro (Hospital Clínic de Barcelona, Barcelona, Spain); Maria López (Hospital Universitari Mútua de Terrassa, Terrassa, Spain); Carol Porta (Hospital Universitari Mútua de Terrassa, Terrassa, Spain); Alex Smithson Amat (Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Spain); Guillen Vidal Escudero (Fundació Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Spain); José Carlos de la Fuente Redondo (Hospital Comarcal Mora d'Ebre, Mora d'Ebre, Spain); Montse Rovira Espés (Hospital Comarcal Mora d'Ebre, Mora d'Ebre, Spain); Arantxa Mera Fidalgo (Hospital de Palamós, Palamós, Spain); Luis Escudero Almazán (Hospital de Palamós, Palamós, Spain); Monserrat Ortega Raya (Hospital Parc Taulí de Sabadell, Sabadell, Spain); Mª Carmen Álvarez Moya (Parc Sanitari Sant Joan de Déu, Sant Boi, Spain); Vicens Diaz-Brito (Parc Sanitari Sant Joan de Déu, Sant Boi, Spain); Laura Grau Palafox (Hospital de Terrassa, Terrassa, Spain); Yésika Angulo Gómez (Hospital de Terrassa, Terrassa, Spain); Anna Besolí Codina (Consorci Hospitalari de Vic, Vic, Spain); Carme Autet Ricard (Consorci Hospitalari de Vic, Vic, Spain); Carlota Hidalgo López (Hospital del Mar, Barcelona, Spain); Elisabeth Lerma-Chippirraz (Hospital General de Granollers, Granollers, Spain); Demelza Maldonado López (Hospital General de Granollers, Granollers, Spain); David Blancas (Consorci Sanitari del Garraf, Vilanova i la Geltrú, Spain); Esther Moreno Rubio (Consorci Sanitari del Garraf, Vilanova i la Geltrú, Spain); Roser Ferrer i Aguilera (Hospital Sant Jaume de Calella, Calella, Spain); Simona Iftimie (Hospital Universitari Sant Joan de Reus, Reus, Spain); Antoni Castro-Salomó (Hospital Universitari Sant Joan de Reus, Reus, Spain); Rosa Laplace Enguídanos (Hospital de Sant Pau i Santa Tecla, Tarragona, Spain); Maria Carmen Sabidó Serra (Hospital de Sant Pau i Santa Tecla, Tarragona, Spain); Núria Bosch Ros (Hospital de Santa Caterina, Salt, Spain); Virginia

Pomar Solchaga (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain); Laura Lázaro Garcia (Hospital Universitari Quirón Dexeus, Barcelona, Spain); Angeles Boleko Ribas (Hospital Universitari Quirón Dexeus, Barcelona, Spain); Jordi Palacín Luque (Pius Hospital de Valls, Valls, Spain); Alexandra Lucía Moise (Pius Hospital de Valls, Valls, Spain); Mª Carmen Fernández Palomares (Hospital Universitari Sagrat Cor, Barcelona, Spain); Santiago Barba Sopeña (Hospital Universitari Sagrat Cor, Barcelona, Spain); Eduardo Sáez Huertas (Clínica Nova Aliança, Lleida, Spain); Sara Burges Estada (Clínica Nova Aliança, Lleida, Spain); Josep María Tricas Leris (Fundació privada Hospital de Mollet, Mollet, Spain); Eva Redon Ruiz (Fundació privada Hospital de Mollet, Mollet, Spain); Montse Brugués (Consorci Sanitari de l'Anoia, Igualada, Spain); Susana Otero Aced (Consorci Sanitari de l'Anoia, Igualada, Spain); Maria Cuscó Esteve (Hospital Comarcal de l'Alt Penedès, Vilafranca del Penedés, Spain); Francisco José Vargas-Machuca (Centre MQ de Reus, Reus, Spain); Mª de Gracia García Ramírez (Centre MQ de Reus, Reus, Spain); Ana Maria Ciscar Bellés (Consorci Hospitalari del Maresme, Mataró, Spain); Elena Vidal Díez (Consorci Hospitalari del Maresme, Mataró, Spain); Mariló Marimón Morón (Hospital Universitari General de Catalunya, Sant Cugat, Spain); Marisol Martínez Sáez (Hospital Universitari General de Catalunya, Sant Cugat, Spain); Josep Farguell (QUIRON Salud, Barcelona, Spain); Mireia Saballs (QUIRON Salud, Barcelona, Spain); Montserrat Vaqué Franco (Hospital de Barcelona, Barcelona, Spain); Leonor Invernón Garcia (Hospital de Barcelona, Barcelona, Spain); Rosa Laplace Enguídanos (Hospital Comarcal del Vendrell, El Vendrell, Spain); Meritxell Guillemat Marrugat (Hospital Comarcal del Vendrell, El Vendrell, Spain); Ana Coloma Conde (Hospital Moisès Broggi, Sant Joan Despí, Spain).

Funding

This study received no external funding. The VINCat Surveillance Program, from which the data was obtained, is supported by public resources from the Catalan Health Service, Department of Health, Generalitat de Catalunya.

Acknowledgements

The authors thank the CERCA Program/Generalitat de Catalunya for institutional support, and all colorectal surgical teams, surgical nurses, infection control teams and quality improvement professionals for all participating hospitals. The authors also thank Michael Maudsley for reviewing the manuscript. M.F-Y. and A.G-G. contributed equally to this study.

Disclosure

Josep M. Badia declares consulting fees from Becton, Dickinson and Company, and Smith&Nephew. The authors declare no other conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online.

Data availability

The research data is prospectively registered and belongs to the Surveillance of Healthcare Related Infections in Catalonia

Program (VINCat), a program from the Catalan Health Service, Department of Health, Generalitat de Catalunya. All data will be made available on request.

Author contributions

Miriam Flores-Yelamos (Conceptualization, Formal analysis, Investigation, Methodology, Writing-original draft, Writingreview & editing), Aina Gomila-Grange (Conceptualization, Formal analysis, Methodology, Writing-original draft, Writingreview & editing), Josep M. Badia (Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Writing-original draft, Writing-review & editing), Alexander Almendral (Data curation, Formal analysis, Investigation, Methodology, Writing-original draft, Writing-review & editing), Ana Vazquez (Formal analysis, Investigation, Methodology, Writing-original draft, Writingreview & editing), David Pares (Methodology, Supervision, Writing-review & editing), Marta Pascual (Investigation, Methodology, Validation, Writing-review & editing), Enric Limón (Conceptualization, Data curation, Methodology, Project administration, Resources, Supervision, Writing-review & editing), Miquel Pujol (Conceptualization, Data curation, Methodology, Project administration, Resources, Supervision, Validation, Writing-review & editing) and Montserrat Juvany (Investigation, Methodology, Supervision, Validation, Writingoriginal draft, Writing-review & editing).

Institutional review board statement

Data extraction was approved by the Institutional Research Board with code 20166009, and the study was approved by the Clinical Research Ethics Committee of Hospital General de Granollers, with code 2021006. The need for informed consent and the provision of an information sheet were waived because data were routinely collected as part of hospital surveillance and quality improvement.

References

- European Centre for Disease Prevention and Control. Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals: 2011–2012. Stockholm: ECDC, 2013. https://www.ecdc.europa.eu/en/ publications-data/surveillance-surgical-site-infections-europe-2010-2011 (accessed 13 August 2021)
- Gallego-Berciano P, Parra LM, Gallego-Munuera M, Cantero M, León-Gómez I, Sastre-García M et al. Encuesta de prevalencia de las infecciones relacionadas con la asistencia sanitaria y uso de antimicrobianos en los hospitales de España, 2022. Bol Epidemiol Semanal 2023;**31**:113–132
- de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control 2009;37:387–397
- Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 2017;96:1–15
- Wick EC, Vogel JD, Church JM, Remzi F, Fazio VW. Surgical site infections in a 'High Outlier' institution: are colorectal surgeons to blame? Dis Colon Rectum 2009;52:374–379

- Harbarth S, Sax H, Gastmeier P. The preventable proportion of nosocomial infections: an overview of published reports. *J Hosp Infect* 2003;54:258–266
- Schreiber PW, Sax H, Wolfensberger A, Clack L, Kuster SP. The preventable proportion of healthcare-associated infections 2005–2016: systematic review and meta-analysis. *Infect Control* Hosp Epidemiol 2018;**39**:1277–1295
- Zywot A, Lau CSM, Stephen Fletcher H, Paul S. Bundles prevent surgical site infections after colorectal surgery: meta-analysis and systematic review. J Gastrointest Surg 2017;21:1915–1930
- Pop-Vicas AE, Abad C, Baubie K, Osman F, Heise C, Safdar N. Colorectal bundles for surgical site infection prevention: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2020;41:805–812
- 10. Anthony T. Evaluating an evidence-based bundle for preventing surgical site infection. Arch Surg 2011;**146**:263
- Hewitt DB, Tannouri SS, Burkhart RA, Altmark R, Goldstein SD, Isenberg GA et al. Reducing colorectal surgical site infections: a novel, resident-driven, quality initiative. Am J Surg 2017;213:36–42
- Weiser MR, Gonen M, Usiak S, Pottinger T, Samedy P, Patel D et al. Effectiveness of a multidisciplinary patient care bundle for reducing surgical-site infections. Br J Surg 2018;105:1680–1687
- Waits SA, Fritze D, Banerjee M, Zhang W, Kubus J, Englesbe MJ et al. Developing an argument for bundled interventions to reduce surgical site infection in colorectal surgery. Surgery 2014;155:602–606
- 14. McGee MF, Kreutzer L, Quinn CM, Yang A, Shan Y, Halverson AL et al. Leveraging a comprehensive program to implement a colorectal surgical site infection reduction bundle in a statewide quality improvement collaborative. Ann Surg 2019;**270**:701–711
- 15. Schlick CJR, Huang R, Brajcich BC, Halverson AL, Yang AD, Kreutzer L et al. Unbundling bundles: evaluating the association of individual colorectal surgical site infection reduction bundle elements on infection rates in a statewide collaborative. Dis Colon Rectum 2022;65:1052–1061
- Vu JV, Collins SD, Seese E, Hendren S, Englesbe MJ, Campbell DA et al. Evidence that a regional surgical collaborative can transform care: surgical site infection prevention practices for colectomy in Michigan. J Am Coll Surg 2018;226:91–99
- Tomsic I, Chaberny IF, Heinze NR, Krauth C, Schock B, von Lengerke T. The role of bundle size for preventing surgical site infections after colorectal surgery: is more better? J Gastrointest Surg 2018;22:765–766
- National Healthcare Safety Network. Surgical Site Infection (SSI) Event: National Healthcare Safety Network. [Internet]. 2023. https://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf? agree=yes&next=Accept (accessed 16 December 2022)
- Horan TC, Robert Gaynes CP, Martone WJ, Jarvis WR, Grace Emori T, Atlanta M. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. *Infect Control Hosp Epidemiol* 1992;13:606–608
- Serra X. Surgical site infection in elective operations for colorectal cancer after the application of preventive measures. Arch Surg 2011;146:606–612
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. *Biometrika* 1983;**70**:41–55
- Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516–524
- Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001;2:259–278

- R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2021. https://www.R-project.org/
- von Elm E ADEMPSGPVJ. STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806–808
- Arroyo-Garcia N, Badia JM, Vázquez A, Pera M, Parés D, Limón E et al. An interventional nationwide surveillance program lowers postoperative infection rates in elective colorectal surgery. A cohort study (2008–2019). Int J Surg 2022;102:106611
- Badia JM, Arroyo-Garcia N, Vázquez A, Almendral A, Gomila-Grange A, Fraccalvieri D *et al*. Leveraging a nationwide infection surveillance program to implement a colorectal surgical site infection reduction bundle: a pragmatic, prospective, and multicenter cohort study. *Int J Surg NLM* (*Medline*) 2023;**109**:737–751
- Dixon LK, Biggs S, Messenger D, Shabbir J. Surgical site infection prevention bundle in elective colorectal surgery. J Hosp Infect 2022;122:162–167
- Brajcich BC, Schlick CJR, Halverson AL, Huang R, Yang AD, Love R et al. Association between patient and hospital characteristics and adherence to a surgical site infection reduction bundle in a statewide surgical quality improvement collaborative. J Am Coll Surg 2022;234:783–792
- Pop-Vicas AE, Young A, Knobloch MJ, Heise C, Bowers B, Safdar N. Surgeons' mental models of surgical site infection: insights into adherence with complex prevention bundles. *Infect Control Hosp Epidemiol* 2022;43:1249–1255
- Pickleman J, Watson W, Cunningham J, Fisher SG, Gamelli R. The failed gastrointestinal anastomosis: an inevitable catastrophe? J Am Coll Surg 1999;188:473–482
- Tonini V, Zanni M. Impact of anastomotic leakage on long-term prognosis after colorectal cancer surgery. World J Gastrointest Surg 2023;15:745–756
- Sciuto A, Merola G, De Palma GD, Sodo M, Pirozzi F, Bracale UM et al. Predictive factors for anastomotic leakage after laparoscopic colorectal surgery. World J Gastroenterol 2018;24: 2247–2260
- Platell C, Barwood N, Dorfmann G, Makin G. The incidence of anastomotic leaks in patients undergoing colorectal surgery. Colorectal Dis 2007;9:71–79
- Shogan BD, Carlisle EM, Alverdy JC, Umanskiy K. Do we really know why colorectal anastomoses leak? J Gastrointest Surg 2013;17:1698–1707
- 36. Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials. Br J Anaesth 2009;103:637–646
- Juvany M, Guirao X, Oliva JC, Pérez JMB. Role of combined post-operative venous lactate and 48 hours C-reactive protein values on the etiology and predictive capacity of organ-space surgical site infection after elective colorectal operation. Surg Infect (Larchmt) 2017;18:311–318
- 38. Olivas AD, Shogan BD, Valuckaite V, Zaborin A, Belogortseva N, Musch M et al. Intestinal tissues induce an SNP mutation in Pseudomonas aeruginosa that enhances its virulence: possible role in anastomotic leak. PLoS One 2012;7:e44326
- Hyoju SK, Adriaansens C, Wienholts K, Sharma A, Keskey R, Arnold W et al. Low-fat/high-fibre diet prehabilitation improves anastomotic healing via the microbiome: an experimental model. Br J Surg 2020;107:743–755

- Konishi T, Watanabe T, Kishimoto J, Nagawa H. Elective colon and rectal surgery differ in risk factors for wound infection. Ann Surg 2006;244:758–763
- Petrosillo N, Drapeau CM, Nicastri E, Martini L, Ippolito G, Moro ML. Surgical site infections in Italian hospitals: a prospective multicenter study. BMC Infect Dis 2008;8:34
- Arezzo A, Migliore M, Chiaro P, Arolfo S, Filippini C, Di Cuonzo D et al. The REAL (REctal Anastomotic Leak) score for prediction of anastomotic leak after rectal cancer surgery. *Tech Coloproctol* 2019;**23**:649–663
- 43. Degiuli M, Elmore U, De Luca R, De Nardi P, Tomatis M, Biondi A et al. Risk factors for anastomotic leakage after anterior resection for rectal cancer (RALAR study): a nationwide retrospective study of the Italian Society of Surgical Oncology Colorectal Cancer Network Collaborative Group. Colorectal Dis 2022;24:264-276
- Park JS, Choi G-S, Kim SH, Kim HR, Kim NK, Lee KY et al. Multicenter analysis of risk factors for anastomotic leakage after laparoscopic rectal cancer excision. Ann Surg 2013;257:665–671
- 45. Gomila A, Carratalà J, Camprubí D, Shaw E, Badia JM, Cruz A et al. Risk factors and outcomes of organ-space surgical site infections after elective colon and rectal surgery. Antimicrob Resist Infect Control 2017;6:40
- Aimaq R, Akopian G, Kaufman HS. Surgical site infection rates in laparoscopic versus open colorectal surgery. American Surgeon 2011;77:1290–1294
- Kiran RP, El-Gazzaz GH, Vogel JD, Remzi FH. Laparoscopic approach significantly reduces surgical site infections after colorectal surgery: data from national surgical quality improvement program. J Am Coll Surg 2010;211:232–238
- Stephensen BD, Reid F, Shaikh S, Carroll R, Smith SR, Pockney P. C-reactive protein trajectory to predict colorectal anastomotic leak: PREDICT study. Br J Surg 2020;107:1832–1837
- 49. Catarci M, Ruffo G, Borghi F, Patriti A, Delrio P, Scatizzi M et al. Anastomotic leakage after elective colorectal surgery: a prospective multicentre observational study on use of the Dutch leakage score, serum procalcitonin and serum C-reactive protein for diagnosis. BJS Open 2020;**4**:499–507
- 50. Facy O, Paquette B, Orry D, Binquet C, Masson D, Bouvier A et al. Diagnostic accuracy of inflammatory markers as early

predictors of infection after elective colorectal surgery. Ann Surg 2016;**263**:961–966

- Giaccaglia V, Salvi PF, Antonelli MS, Nigri G, Pirozzi F, Casagranda B et al. Procalcitonin reveals early dehiscence in colorectal surgery. Ann Surg 2016;263:967–972
- Guirao X, Juvany M, Franch G, Navinés J, Amador S, Badía JM. Value of C-reactive protein in the assessment of organ-space surgical site infections after elective open and laparoscopic colorectal surgery. Surg Infect (Larchmt) 2013;14:209–215
- Ortega-Deballon P, Radais F, Facy O, d'Athis P, Masson D, Charles PE et al. C-reactive protein is an early predictor of septic complications after elective colorectal surgery. World J Surg 2010;34:808–814
- Yeung DE, Peterknecht E, Hajibandeh S, Hajibandeh S, Torrance AW. C-reactive protein can predict anastomotic leak in colorectal surgery: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:1147–1162
- Singh PP, Zeng ISL, Srinivasa S, Lemanu DP, Connolly AB, Hill AG. Systematic review and meta-analysis of use of serum C-reactive protein levels to predict anastomotic leak after colorectal surgery. Br J Surg 2014;101:339–346
- 56. Cousin F, Ortega-Deballon P, Bourredjem A, Doussot A, Giaccaglia V, Fournel I. Diagnostic accuracy of procalcitonin and C-reactive protein for the early diagnosis of intraabdominal infection after elective colorectal surgery. Ann Surg 2016;**264**:252–256
- Gozalichvili D, Binquet C, Boisson C, Guiraud A, Facy O, Ortega-Deballon P. Early detection of anastomotic leak with C-reactive protein increases the chances of anastomotic salvage. Colorectal Dis 2023;25:728–737
- de Lastours V, Poirel L, Huttner B, Harbarth S, Denamur E, Nordmann P. Emergence of colistin-resistant Gram-negative Enterobacterales in the gut of patients receiving oral colistin and neomycin decontamination. J Infect 2020;80:578–606
- Pochhammer J, Kramer A, Schäffer M. Enterokokken und postoperative Wundinfektionen. Der Chirurg 2017;88:377–384
- Múñez E, Ramos A, Espejo T, Vaqué J, Sánchez-Payá J, Pastor V et al. Microbiología de las infecciones del sitio quirúrgico en pacientes intervenidos del tracto digestivo. Cir Esp 2011;89: 606–612